Multiprofile Hospital For Active Treatment Pazardzik AD
- Address
- lock Available on a paid plan
Cardiovascular Research
The department focuses on cardiovascular disease and related conditions, evaluating new therapies aimed at reducing heart attacks, stroke risk, and heart failure.
- Heart failure with reduced ejection fraction
- High cardiovascular risk patients
- Acute myocardial infarction
- Ischemic stroke prevention
- Hypertriglyceridemia management
Multiprofile Hospital For Active Treatment Pazardzik AD supports these studies through a dedicated cardiology team.
Respiratory & Metabolic Studies
Research includes chronic obstructive pulmonary disease and metabolic disorders such as severe hypertriglyceridemia, aiming to improve patient outcomes with novel agents.
- COPD with type 2 inflammation
- Severe hypertriglyceridemia
- Hypertension management
- Metabolic risk reduction
The hospital’s integrated care model enables simultaneous assessment of lung function and metabolic health.
Neurology & Immunology
Trials address multiple sclerosis and immune‑mediated conditions, testing therapies that may slow disease progression and modulate immune response.
- Non‑relapsing secondary progressive MS
- Relapsing MS
- Immune system modulation
- Neuroinflammation
Patients benefit from coordinated neurology and immunology expertise at the site.
Dermatology Research
The unit investigates chronic spontaneous urticaria and vitiligo, focusing on treatments that reduce skin symptoms and improve quality of life.
- Chronic spontaneous urticaria activity
- Nonsegmental vitiligo
- Skin inflammation control
Dermatology specialists collaborate with cardiology to monitor systemic effects of therapies.
Infectious Disease Studies
A pediatric program evaluates new antibiotics for complicated urinary tract infection and acute pyelonephritis, ensuring safety in young patients.
- Complicated urinary tract infection in children
- Acute pyelonephritis in pediatric population
The hospital’s pediatric unit provides a safe environment for these critical studies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ionis Pharmaceuticals Inc.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multiprofile Hospital For Active Treatment Pazardzik AD
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2023-05-17 | 2023-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.